Cohort Study

Risk factors for early morbidity and mortality following pancreatoduodenectomy with concomitant vascular reconstruction

Tiffany Y. Lim, I. Michael Leitman *

Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, United States

ARTICLE INFO

Keywords:
Pancreatic resection
Portal vein
Superior mesenteric artery
Pancreas
Carcinoma

ABSTRACT

Background: Locally advanced pancreatic tumors may require vascular reconstruction for complete resection. However, pancreatoduodenectomy with vascular resection (PDVR) remains a subject of debate due to increased complications.

Methods: Patients were identified using the ACS NSQIP Participant User Data Files from 2014 to 2019. Results: The 30-day mortality rate was 2.7%; major complications occurred in 32.2%. There is an increasing trend of PDVR in patients requiring pancreatectomy. There were no significant differences in mortality between PDVR with vein, artery, or venous and arterial resections. High BMI and postoperative biliary stent were risk factors for early complications. High BMI and COPD increased risk of early mortality. Chemotherapy and chemoradiotherapy were negative predictors for early morbidities and mortality, respectively.

Conclusion: This study identifies the predictors of early morbidity and mortality in PDVR. The results of this study may assist decision making in perioperative management to optimize overall survival and guide additional research.

1. Introduction

Pancreatic cancer has the lowest 5-year survival rate (10%) among the most common types of cancer and its mortality rate continued to increase by 0.3% since 2000 [1]. While complete resection with negative margin has shown the most significant benefit in long-term survival, not all pancreatic tumors are resectable [2-5]. In the most recent National Comprehensive Cancer Network (NCCN) Guidelines (version 1.2021), a resectable tumor was defined as “no arterial tumor contact (celiac axis, superior mesenteric artery, or common hepatic artery)” and/or “no tumor contact with the superior mesenteric vein or portal vein or ≤ 180° contact without vein contour irregularity.” [6] However, due to the lack of effective screening program and natural history of the disease; patients commonly remain asymptomatic until they present with a locally advanced tumor [2].

Historically, involvement of adjacent vasculature was considered a contraindication for resection. Earlier studies of neoadjuvant therapy failed to show sufficient survival benefit and tumor shrinkage and even increased rates of complications [7]. However, more recent neoadjuvant therapy trials have shown survival benefits and increased in R0 resection rate [8-11]. As a result of the success with neoadjuvant therapy regimens and operative technical improvement, pancreatoduodenectomy with vascular resection (PDVR) has been increasingly utilized and recommended for patients with borderline resectable pancreatic cancer [6,12].

Despite the increase in utilization, there are conflicting results regarding the safety and efficacy of PDVR. One meta-analysis study that consolidated several studies with smaller sample sizes showed that PDVR, specifically superior mesenteric arterial (SMA) resection, results in a higher mortality rate at 1-year and 3-years compared to pancreaticoduodenectomy without SMA resection [13]. Worni analyzed a large multi-institutional database, Nationwide Inpatient Sample, from 2000 to 2009, and showed no significant difference for in-hospital mortality with PDVR compared to pancreatoduodenectomy alone. Interestingly, in the same study, PDVR had significantly higher in-hospital mortality in the highest hospital volume quartile [14]. In contrast, another study utilizing The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database showed a significant increase in 30-day mortality following PDVR [15]. A smaller study investigated long-term outcome and found no significant survival differences between PDVR and standard PD at one year and three years post-op but a significantly lower survival rate in PDVR at five
years post-op. Regardless, the survival rate after PDVR was significantly higher than patients who received palliative chemoradiation without surgery [16].

To date, there are no published studies utilizing a multi-institutional database to investigate specific perioperative patient-specific and modifiable risk factors that predispose to early complications and mortality in PDVR. In addition, previous studies have been limited in comparing outcomes in different types of vascular resection in PDVR. Therefore, the aims of this study were to (1) assess trend of utilization of PDVR and its complications using a multi-institutional, risk-adjusted database from 2014 to 2019, and (2) identify modifiable perioperative factors that predispose to greater risks for early morbidity and mortality after PDVR.

2. Methods

2.1. Data Collection and Patient selection

The American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Participant User Files and Procedure Targeted Files from 2014 to 2019 were analyzed retrospectively. The ACS-NSQIP provided an extensive pre-operative and peri-operative dataset as well as risk-adjusted 30-day postoperative morbidity and mortality. All data were recorded by trained personnel from over 700 healthcare institutions. There were no patient or hospital identifiers included in the Participant User Files. This project received human research exempt determination by the institutional review board (IRB-20-02957).

Patients who underwent pancreatoduodenectomy were identified using the Current Procedural Terminology (CPT) codes 48150, 48152, 48153, 48154, 48155. Patients who were identified to have disseminated cancer preoperatively were excluded as they are typically identified as non-surgical candidates. Patients with postoperative diagnosis specific to pancreatic cancer were selected using the International Classification of Diseases (ICD-9 and ICD-10), including benign neoplasm of pancreas (D13.6), benign neoplasm of pancreas except islets of Langerhans (211.6), malignant neoplasm of pancreas (C25), malignant neoplasm of head of pancreas (157, C25.0), malignant neoplasm of body of pancreas (157.1, C25.1), malignant neoplasm of tail of pancreas (157.2, C25.2), malignant neoplasm of pancreatic duct (157.3, C25.3), malignant neoplasm of endocrine pancreas (157.4, C25.4), Malignant neoplasm of other specified sites of pancreas (157.8, C25.7), malignant neoplasm of unspecified pancreas (157.9, C25.9), malignant neoplasm of overlapping sites of pancreas (C25.8). Information of types of vascular resections were extracted from procedure targeted files. All dataset preparation and statistical analyses were performed using R studio Desktop (Version 1.1.463 - Vienna, Austria) [17]. This work has been reported in line with the STROCSS criteria [18].

The American College of Surgeons National Surgical Quality Improvement Program and the hospitals participating in the ACS NSQIP are the source of the data used herein; they have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.

2.2. Outcomes of interest

30-day mortality and major morbidities were the primary outcomes of interest. Major morbidities included occurrences of any of the following: dehiscence, stroke, cardiac arrest requiring CPR, myocardial infarction, pneumonia, dependence on a mechanical ventilator for more than 48 h, unplanned reintubation, acute renal failure, progressive renal insufficiency, sepsis, septic shock, superficial incisional surgical site infection, deep incisional surgical site infection, organ space surgical site infection, pulmonary embolism, deep vein thrombosis (DVT) and return to operation room.

2.3. Statistical analysis

Chi-square and ANOVA analyses were used to investigate significance of patient demographic and comorbid conditions between three postoperative outcome groups – uncomplicated, early morbidities but survival at 30 days, and 30-day mortality. Post-hoc univariate analyses were performed to identify specific outcome groups that were significant.

Multivariable logistic regression models adjusted for types of vascular resections and comorbidities were constructed to identify perioperative risk factors that significantly increase the probability of developing mortality and major morbidities after PDVR. Modifiable risk factors with adequate sample size were selected when building multivariable logistic regression models.

All tests of significance were determined at p-value < 0.05.

3. Results

From 2014 to 2019, there were 13,479 patients in NSQIP database that underwent pancreatoduodenectomy for pancreatic cancer, of which 3146 underwent PDVR. The percentage of PDVR among patients who underwent resection for pancreatic cancer significantly increased from 21.7% in 2014 to 24.8% in 2019 (p = 0.022). The 30-day mortality rate was 2.7%. Major complications without mortality occurred in 32.2%. There were no significant trends observed early mortality (p = 0.150) or early morbidities (p = 0.417) during the study period (Fig. 1).

A comparison of the demographic and comorbid characteristics between patients and postoperative outcomes in provided in Table 1. There were significant differences among the three postoperative outcome groups (no complications, early morbidity, and postoperative mortality) in patients for BMI, proportion of COPD, use of anti-hypertension medication, and preoperative biliary stent placement. Post-hoc analyses reveals that patient with an uncomplicated postoperative course had a higher proportion of preoperative chemotherapy. There was also a significant increase in proportion of patients that developed early morbidity in patients that underwent neoadjuvant chemoradiotherapy.

Intraoperative findings were compared to examine the impact on postoperative outcomes (Table 2). There were no significant differences between postoperative outcomes in terms of TNM stage or duct size. Post-hoc analyses revealed that there were significantly less patients who had an uncomplicated postoperative course among patients with a “soft” gland texture.

Rates for complications were compared between different types of vascular resection – vein, artery, and vein and artery (Table 3). There were significant differences of occurrences of myocardial infarction and DVT amongst different types of vascular resection.

Risk factors for early major morbidity and mortality were identified through multivariable logistic regression models adjusted for types of vascular resections and comorbidities. Regardless of types of vascular resection, obesity, presence biliary stent preoperatively were independent positive risk factors that increased odds of developing any early major morbidity (Fig. 2). Neoadjuvant chemotherapy is a negative predictor for early morbidity. Obesity and COPD were predictors of 30-day mortality while neoadjuvant chemoradiotherapy were protective for early mortality (see Fig. 3).

4. Discussion

PDVR has been a subject of debate in the management of locally advanced and borderline resectable pancreatic tumors due to a poor prognosis. Previous multi-institutional studies have reported an increased incidence of complications and mortality in PDVR compared to pancreatoduodenectomy alone [14,15,19,20]. However, as resection with negative margin remains the only viable treatment with long-term survival benefits, PDVR has been increasingly performed for locally
advanced pancreatic tumors. Previous studies have reported an increase of PDVR from 0.7% in 2000 to 6.0% in 2009 among patients requiring pancreatic resection for malignant pancreatic disease [14]. In the present study that included pancreatic resection cases for both benign and malignant pancreatic disease, there was also a significant increase in implementation of vascular resection. Despite an increase in cases with vascular resection, there does not appear to be any significant change in the rate of early morbidity and mortality over the years. Therefore, this study aims to investigate risk factors that predispose patients to early morbidity and mortality following PDVR.

Previous studies utilizing NSQIP data have disagreed on the significance of types of vascular resections in early morbidity or mortality rate. Zettervall reports a significantly higher early mortality rate with arterial procedures among pancreatoduodenectomy from 2014 to 2015 [21]. Beane et al. reported no significant difference in overall morbidity and mortality rate between vein only resection and resection involving arterial structures following pancreaticoduodenectomy from 2011 to 2012 [22]. Both studies utilize a short study period with a smaller sample size. In the present study, we were able to separate vascular reconstructive procedures into vein only, artery only and concomitant vein and artery. Our results suggest that there was no significant difference in morality amongst different types of vascular resection in pancreatoduodenectomy. Our finding suggests that anticipation of arterial resection should not be a deterring factor for patients requiring a more extensive pancreatoduodenectomy.

Multivariable analyses suggest that a higher BMI might be a

![Graph showing trend of PDVR Utilization, Major Complications and Mortality.]

Chi-square analysis showed significant increase in percentages of PDVR among all pancreatoduodenectomy cases from 2014 to 2019 in the NSQIP database ($P = 0.022$). No significant changes were observed in postoperative mortality ($p = 0.150$) or morbidities ($p = 0.417$).

### Table 1
Demographics and patient characteristics of patients underwent PDVR.

| Patient Characteristics          | Total (N = 3146) | No complications (n = 2050) | Morbidity (n = 1012) | Death (n = 84) | p value |
|----------------------------------|-----------------|-----------------------------|----------------------|----------------|---------|
| **Age**                          |                 |                             |                      |                |         |
| Age 65.95                        | 66.04           | 65.59                       | 67.98                | 0.093          |
| **BMI**                          |                 |                             |                      |                |         |
| BMI 26.46                        | 26.17           | 26.92                       | 28.24                | <0.001         |
| **Race**                         |                 |                             |                      |                |         |
| White                            | 2226            | 1474                        | 685                  | 67             |
| Black or African American        | 214             | 138                         | 73                   | 3              |
| American Native or Alaska Native|                 |                             | 1                    | 0              |
| Asian                            | 150             | 102                         | 45                   | 3              |
| Native Hawaiian or Pacific Islander| 5            | 2                            | 3                   | 0              |
| Others/Unidentified              | 546             | 330                         | 205                  | 11             |
| Female                           | 1545            | 1038                        | 462                  | 45             |
| Female 49.1%                     | 50.6%           | 50.6%                       | 50.6%                | 0.025          |
| **Smoker**                       |                 |                             |                      |                |         |
| Smoke 15.4%                      | 8                | 0.39                        | 0                    | 0.000          |
| Diabetes                         | 1014            | 646                         | 339                  | 29             |
| Diabetes 32.23%                  | 31.5%           | 33.5%                       | 34.52%               | 0.489          |
| Ascites                          | 14              | 8                           | 6                    | 0              |
| Ascites 0.45%                    | 0.39%           | 0.59%                       | 0.000                | 0.602          |
| HTN medication                   | 1655            | 1040                        | 538                  | 57             |
| HTN medication 52.61%            | 50.73%          | 50.14%                      | 67.86%               | 0.003          |
| COPD                             | 127             | 70                          | 47                   | 10             |
| COPD 4.04%                       | 3.41%           | 4.64%                       | 11.90%               | <0.001         |
| Transfusion                      | 28              | 18                          | 8                    | 2              |
| Transfusion 0.89%                | 0.88%           | 0.79%                       | 2.38%                | 0.327          |
| Bleeding Disorder                | 115             | 69                          | 43                   | 3              |
| Bleeding Disorder 3.66%          | 3.37%           | 4.25%                       | 3.57%                | 0.472          |
| Jaundice                         | 1412            | 906                         | 460                  | 46             |
| Jaundice 44.88%                  | 44.78%          | 46.00%                      | 54.76%               | 0.181          |
| Preoperative biliary stent       | 1947            | 1226                        | 665                  | 56             |
| Preoperative biliary stent 61.89%| 61.98%          | 67.10%                      | 72.73%               | 0.006          |
| Neadjuvant therapy               |                 |                             |                      |                |         |
| Chemotherapy                     | 881             | 615                         | 244                  | 22             |
| Chemotherapy 28.00%              | 30.00%          | 24.11%                      | 26.19%               | <0.001         |
| Radiotherapy                     | 74              | 43                           | 28                   | 3              |
| Radiotherapy 2.35%               | 2.10%           | 2.77%                       | 3.57%                | 0.572          |
| Chemoradiotherapy                | 612             | 377                         | 227                  | 8              |
| Chemoradiotherapy 19.45%         | 18.39%          | 22.43%                      | 9.52%                | 0.572          |
| None                             | 1579            | 1015                        | 513                  | 51             |
| None 50.19%                      | 49.51%          | 50.69%                      | 60.71%               | 0.607          |
### Table 2
Intraoperative characteristics.

|              | No Complications | Morbidity | Death | p value |
|--------------|------------------|-----------|-------|---------|
|              | n     | %      | n     | %      | n     | %      |       |
| T stage      |       |        |       |        |       |        |       |
| T0           | 13    | 0.66%  | 11    | 1.13%  | 0     | 0.00%  | 0.414 |
| T1           | 202   | 10.22% | 93    | 9.58%  | 5     | 6.67%  |        |
| T2           | 539   | 27.26% | 276   | 28.42% | 16    | 21.33% |        |
| T3           | 1175  | 59.43% | 559   | 57.57% | 51    | 68.00% |        |
| T4           | 44    | 2.23%  | 27    | 2.78%  | 3     | 4.00%  |        |
| Tis          | 4     | 0.20%  | 5     | 0.51%  | 0     | 0.00%  |        |
| M stage      |       |        |       |        |       |        | 0.708 |
| M0           | 1443  | 97.90% | 716   | 97.55% | 55    | 96.49% |        |
| M1           | 31    | 2.10%  | 18    | 2.45%  | 2     | 3.51%  |        |
| N stage      |       |        |       |        |       |        | 0.411 |
| N0           | 678   | 34.52% | 346   | 35.67% | 30    | 40.00% |        |
| N1           | 1179  | 60.03% | 568   | 58.56% | 38    | 50.67% |        |
| N2           | 107   | 5.45%  | 56    | 5.77%  | 7     | 9.33%  |        |
| Gland Texture|       |        |       |        |       |        | 0.042 |
| Soft         | 298   | 20.03% | 165   | 25.11% | 16    | 31.37% |        |
| Intermediate | 205   | 13.78% | 89    | 13.55% | 6     | 11.76% |        |
| Hard         | 985   | 66.20% | 403   | 61.34% | 29    | 56.86% |        |
| Duct Size    |       |        |       |        |       |        | 0.060 |
| <3 mm        | 284   | 18.39% | 164   | 23.60% | 10    | 19.61% |        |
| 3–6 mm       | 918   | 59.46% | 398   | 57.27% | 31    | 60.78% |        |
| >6 mm        | 342   | 22.15% | 133   | 19.14% | 10    | 19.61% |        |

### Table 3
Early complications in PDVR with vein, artery and vein and artery resection.

| Complication                        | Total | Vein | Artery | Vein and artery | p-value |
|-------------------------------------|-------|------|--------|-----------------|---------|
|                                    | n     | %    | n     | %    | n     | %    |       |
| Death                               | 84    | 2.7% | 55    | 2.29% | 11    | 4.37% | 18    | 3.65% | 0.051 |
| Stroke                              | 16    | 0.5% | 11    | 0.46% | 3     | 1.19% | 2     | 0.41% | 0.281 |
| Myocardial Infarction               | 40    | 1.3% | 37    | 1.54% | 3     | 1.19% | 0     | 0.00% | 0.021 |
| Pneumonia                           | 132   | 4.2% | 94    | 3.92% | 16    | 6.35% | 22    | 4.66% | 0.177 |
| On Ventilator greater than 48 Hours | 131   | 4.2% | 100   | 4.16% | 15    | 5.95% | 16    | 3.25% | 0.216 |
| Unplanned reintubation              | 112   | 3.6% | 78    | 3.25% | 15    | 5.95% | 19    | 3.85% | 0.082 |
| Acute Kidney Injury                 | 41    | 1.3% | 30    | 1.25% | 4     | 1.59% | 7     | 1.42% | 0.876 |
| Sepsis                              | 293   | 9.3% | 225   | 9.37% | 26    | 10.32%| 42    | 8.52% | 0.712 |
| Septic Shock                        | 113   | 3.6% | 86    | 3.58% | 12    | 4.76% | 15    | 3.04% | 0.490 |
| Superficial Incisional SSI          | 251   | 8.0% | 192   | 8.00% | 20    | 7.94% | 39    | 7.91% | 0.998 |
| Wound Infection                     | 23    | 0.7% | 19    | 0.79% | 1     | 0.40% | 3     | 0.61% | 0.737 |
| Organ Space SSI                     | 390   | 12.4%| 292   | 12.16%| 42    | 16.67%| 56    | 11.36%| 0.089 |
| Dehiscence                          | 39    | 1.2% | 31    | 1.39% | 5     | 1.98% | 4     | 0.81% | 0.595 |
| Pulmonary Embolism                  | 41    | 1.3% | 32    | 1.33% | 5     | 1.98% | 4     | 0.81% | 0.396 |
| Deep Vein Thrombosis                | 167   | 5.3% | 141   | 5.87% | 9     | 3.57% | 17    | 3.45% | 0.040 |
| Pancreatic Fistula                  | 315   | 10.0%| 245   | 10.25%| 27    | 10.93%| 43    | 9.01% | 0.650 |

**SSI** surgical site infection.

**Fig. 2.** Preoperative Patient Characteristics as Predictors for 30-Day Major Complications.

Generalized regression model was built to identify specific preoperative factors that predispose to early morbidities. Odds ratio were risk-adjusted by types of vascular resection. **BMI** Body Mass Index, **CI** Confidence Interval, **COPD** chronic obstructive pulmonary disease, **CHF** congestive heart failure.
The value of neoadjuvant therapies in resectable and borderline resectable pancreatic cancer has been a topic of debate. In the present study, we categorized neoadjuvant therapies into chemotherapy, radiotherapy, and chemoradiotherapy. After adjusted for types of vascular resections and comorbidities, patients who received chemotherapy were found to have lower risks of developing early morbidities while patients who received chemoradiotherapy have lower risks of 30-day mortality. Earlier studies have raised concern for increased complication rates and minimal survival benefit in patients who received neoadjuvant therapies [7–9]. Therefore, neoadjuvant therapies were only recommended in higher-volume hospitals especially in the setting of borderline resectable pancreatic tumor [6]. However, recent studies have shown significantly increased survival benefits in neoadjuvant therapies. A systematic review that included 38 studies demonstrated significant improvement in median survival in patients receiving neoadjuvant therapies followed by resection versus patients receiving immediate surgery (26.1 months versus 15.0 months). There was also a significantly higher R0 rate in the neoadjuvant groups [10]. Furthermore, a prospective clinical trial (PREOPANC1) that randomized patients into preoperative chemoradiotherapy and immediate surgery reported an overall significant survival benefits in patients who received neoadjuvant therapies (median 17.1 vs. 13.5 months) as well as an increase in R0 resection rate (65% vs. 31%) [11]. Because of the emerging new evidence of the potential benefit of neoadjuvant therapies, recent recommendations of PDVR suggest an additional rationale for neoadjuvant treatment in borderline resectable pancreatic cancer [6, 12].

There are limitations in analyzing effect of neoadjuvant therapies on postoperative outcome in current study. As this study utilized a multi-institutional dataset, the neoadjuvant therapy protocols included may have been heterogenous and specific protocols used for each patient were not available for analyses. Nevertheless, despite the acknowledgement that most studies to date report heterogeneous neoadjuvant protocols, current NCCN guidelines recommend neoadjuvant therapy instead of immediate resection to improve R0 resection rates [6].

Other limitations in the present study include inability to evaluate long-term survival and outcomes. Information for vascular procedures were limited to involvement of vein, artery or vein and artery; details of portal vein resection grades or extent of vascular procedure could not be analyzed. Information regarding reconstruction methods such as primary repair or autologous venous patch were also unavailable. While the procedure targeted dataset provided some pancreatotomy specific complications such as pancreatic fistula, other known complications such as portal vein thrombosis were not recorded. Furthermore, whether the vascular resection was planned preoperatively or an intra-operative decision due to events in the operating room were unknown.

While the results of this study should be interpreted within the context of the above limitations, this study presents valuable findings with the largest and most up to date cohort of patients undergoing...
PDVR. This study identifies specific preoperative patient-specific factors and modifiable risk factors, such as higher BMI and preoperative biliary stent placement as risk factors and neoadjuvant therapy as a negative predictor. The goal is to create a patient-centered and personalized perioperative planning to optimize surgical outcomes.

5. Conclusion

This study reports the largest multi-institutional series that investigates the outcomes following PDVR. The results suggest that, despite a trend of increase utilization of PDVR in patients undergoing pancreatic resection, the incidence of 30-day morbidity and mortality remains unchanged. The study identified preoperative risk factors that predispose patients to early morbidity and mortality. Chemotherapy was an independent predictor for decreased early morbidity, whereas chemoradiation therapy was an independent predictor for improved early survival. The results of this study may assist decision making for perioperative management to improve overall survival following PDVR and guide areas of focus for future studies.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Ethical approval

Institutional Review Board (IRB) of the Icahn School of Medicine at Mount Sinai (IRB-20-02957).

Sources of funding

None.

Author contribution

Study design: I. Michael Leitman, Tiffany Y. Lim. 
Data Collection: I. Michael Leitman. 
Data analysis: Tiffany Y. Lim. 
Writing: I. Michael Leitman, Tiffany Y. Lim.

Registration of research studies

1. Name of the registry: Research Registry.
2. Unique Identifying number or registration ID: researchregistry6923.
3. Hyperlink to your specific registration (must be publicly accessible and will be checked): https://www.researchregistry.com/browse-the-registry#home/registrationdetails/60d5ef54fe99b3001ee01db2/

Guarantor

I. Michael Leitman, MD.

Consent

N/A.

Declaration of competing interest

None.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.amsu.2021.102587.

References

[1] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, CA A Cancer J. Clin. 71 (1) (2021) 7–33, https://doi.org/10.3322/caac.21654.
[2] S.G. Barreto, J.A. Windsor, Justifying vein resection with pancreaticoduodenectomy, Lancet Oncol. 17 (3) (2016) e118–e124, https://doi.org/10.1016/S1470-2045(15)00463-5.
[3] T.J. Howard, J.E. Krug, J. Yu, et al., A margin-negative 80 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer, J. Gastrointest. Surg. 10 (10) (2006) 1338–1346, https://doi.org/10.1007/s11605-006-0908-3.
[4] O. Strobel, T. Hank, U. Hinz, et al., Pancreatic cancer surgery, Ann. Surg. 265 (3) (2017) 565–573, https://doi.org/10.1097/SLA.0000000000001731.
[5] M. Wagner, C. Redaelli, M. Lietz, C.A. Seiler, H. Friess, M.W. Büchler, Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma, Br. J. Surg. 91 (5) (2004) 586–594, https://doi.org/10.1002/bjs.4484.
[6] M.A. Tempero, M.P. Malafa, M. Al-Hawary, et al., NCCN Guidelines, Pancreatic Adenocarcinoma NCCN Evidence Blocks, 2020, Version 1.2021. https://www.nccn.com (Accessed 15 January 2021).
[7] J.D. Ahlgren, Chemotherapy for pancreatic carcinoma, Cancer 78 (3 SUPPL.) (1996) 654–663, https://doi.org/10.1002/1097-0142(19960801)78:3<654::AID-CNCR46>3.0.CO;2-V.
[8] J.D. Allendorf, M. Lauermand, A. Bill, et al., Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival, J. Gastrointest. Surg. 12 (1) (2008) 91–100, https://doi.org/10.1007/s11605-007-0296-7.
[9] P. Vento, H. Mustonen, T. Joensuu, P. Karkkainen, E. Kivilaakso, T. Kiviluoto, Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer, World J. Gastroenterol. 13 (21) (2007) 2945–2951, https://doi.org/10.3748/wjg.v13.i21.2945.
[10] E. Versteijne, J.A. Vogel, M.G. Besselink, et al., Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer, Br. J. Surg. 105 (8) (2018) 946–958, https://doi.org/10.1002/bjs.11070.
[11] E. Versteijne, C.H.J. van Eijck, C.J.A. Punt, et al., Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial, Trials 17 (1) (2016) 1–4, https://doi.org/10.1186/s13063-016-1256-z.
[12] J.R. Delpero, A. Sauvanet, Vascular resection for pancreatic cancer: 2019 French recommendations based on a literature review from 2008 to 6-2019, Front. Oncol. 10 (February) (2020) 1–18, https://doi.org/10.3389/fonc.2020.00040.
[13] N. Mollberg, N.N. Bahhari, M. Koch, et al., Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis, Ann. Surg. 254 (6) (2011) 882–893, https://doi.org/10.1097/SLA.0b013e3182123a99.
[14] M. Worni, A.W. Castleberry, B.M. Clary, et al., Goncomitant vascular reconstruction during pancreatectomy for malignant disease: a propensity score-adjusted, population-based trend analysis involving 10 206 patients, JAMA Surg. 148 (4) (2013) 331–338, https://doi.org/10.1001/jamasurg.2013.1058.
[15] A.W. Castleberry, R.R. White, S.G. De La Fuente, et al., The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons national surgical quality improvement program database, Ann. Surg Oncol. 19 (13) (2012) 4068–4077, https://doi.org/10.1245/s10434-012-2588-y.
[16] M.D. Sigoi, R.R. Narayan, J.S. Lane, et al., Vascular reconstruction plays an important role in the treatment of pancreatic adenocarcinoma, J. Vasc. Surg. 61 (2) (2015) 475–480, https://doi.org/10.1016/j.jvs.2014.09.003.
[17] R Core Team, R: A language and environment for statistical computing, R Foundation for Statistical Computing, Vienna, Austria (2018). https://www.R-project.org/.
[18] R.A. Agata, A. Abdall-Razak, E. Crossley, N. Dowlut, C. Iosifidis, G. Mathew, for the STROCSS Group, The STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery, Int. J. Surg. 72 (2019) 156–165.
[19] J.D. Beane, M.G. House, S.C. Pitt, et al., Distal pancreatectomy with celiac axis resection: what are the added risks? HPB 17 (2015) 777–784, https://doi.org/10.1111/hpb.12455, Blackwell Publishing Ltd.
[20] J.R. Delpero, J.M. Boher, A. Sauvanet, et al., Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the association française de Chirurgie, Ann. Surg. Oncol. 22 (6) (2015) 1874–1883, https://doi.org/10.1245/s10434-014-4040-3.
[21] S.L. Zettervall, T. Ju, J.L. Holmzacher, et al., Arterial, but not venous reconstruction increases 30-day morbidity and mortality in pancreaticoduodenectomy, J. Gastrointest. Surg. (2019) 1–7, https://doi.org/10.1007/s11665-019-04211-2.
[22] J.D. Beane, M.G. House, S.C. Pitt, et al., Pancreaticoduodenectomy with venous or arterial resection: a NSQIP propensity score analysis, HPB (2016), https://doi.org/10.1111/hpb.12455.
[23] A. Shamali, V. Shelat, B. Jaber, et al., Impact of obesity on short and long term results following a pancreatic-duodenectomy, Int. J. Surg. 42 (2017) 191–196, https://doi.org/10.1016/j.ijsu.2017.04.058.
[24] E. Rosso, S. Cannedi, P. Pessaux, et al., The role of “Fatty Pancreas” and of BMI in the occurrence of pancreatic fistula after pancreaticoduodenectomy, J. Gastrointest. Surg. 13 (10) (2009) 1845–1851, https://doi.org/10.1007/s11605-009-0974-8.
[25] A.O. Whipple, W.B. Parsons, C.R. Mullins, Treatment of carcinoma of the ampulla of vater, Ann. Surg. 102 (4) (1935) 763–779, https://doi.org/10.1097/00000658-193510000-00025.

[26] Z.Q. Ng, A.E. Suthananthan, S. Rao, Effect of preoperative biliary stenting on post-operative infectious complications in pancreaticoduodenectomy, Ann. Hepato-Biliary-Pancreatic Surg. 21 (4) (2017) 212, https://doi.org/10.14701/ahbps.2017.21.4.212.

[27] P. Jagannath, V. Dhir, S. Shrikhande, R.C. Shah, P. Mullerpatan, K.M. Mohandas, Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy, Br. J. Surg. 92 (3) (2005) 356–361, https://doi.org/10.1002/bjs.4864.

[28] W. Ngu, M. Jones, C.P. Neal, A.R. Dennison, M.S. Metcalfe, G. Garcia, Preoperative biliary drainage for distal biliary obstruction and post-operative infectious complications, ANZ J. Surg. 83 (4) (2013) 280–286, https://doi.org/10.1111/j.1445-2197.2012.05296.x.

[29] M.E. Sewnath, T.M. Karsten, M.H. Prins, E.J.A. Rauws, H. Obertop, D.J. Gouma, A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice, Ann. Surg. 236 (1) (2002) 17–27, https://doi.org/10.1097/00000658-200207000-00005.

[30] G. Younan, S. Tsai, D.B. Evans, K.K. Christians, Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer, 2016, https://doi.org/10.1016/j.anuc.2016.07.005.

[31] R.L. Smoot, J.D. Christein, M.B. Farnell, Durability of portal venous reconstruction following resection during pancreaticoduodenectomy, J. Gastrointest. Surg. 10 (10) (2006) 1371–1375, https://doi.org/10.1016/j.gassur.2006.09.001.

[32] M.D. Chandrasegaram, G.D. Elick, W. Lee, et al., Anticoagulation policy after venous resection with a pancreatectomy: a systematic review, HPB 16 (8) (2014) 691–698, https://doi.org/10.1111/hpb.12205.